A Randomized, Double-Blind, Multicentre, Phase II Controlled Trial Assessing Zactima (Vandetanib) Against Placebo in Prolonging the Off-Treatment Interval in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy.
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2016
At a glance
- Drugs Vandetanib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms ZENITH
- 31 Aug 2018 Biomarkers information updated
- 09 Dec 2010 Planned End Date changed from 1 Apr 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 03 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.